Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
* Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage III - IV. * Assess the toxicity and maximum tolerated dose of bortezomib administered in combination with GIFOX chemotherapy.
Epistemonikos ID: 755cc098a82d5ba4574fdb63935f35b61102b071
First added on: May 17, 2024